Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
0.5830
+0.0208 (3.70%)
Oct 23, 2026, 12:23 PM EDT - Market open
Akebia Therapeutics Revenue
Akebia Therapeutics had revenue of $49.13M in the quarter ending June 30, 2026, a decrease of -21.36%. This brings the company's total for the last twelve months to $219.06M, up 7.52% year-over-year. In the year 2025, Akebia Therapeutics had annual revenue of $236.20M with 47.46% growth. That makes Akebia Therapeutics the 16,798th largest company in the world by revenue and 2,823rd in the United States.
Revenue (ttm)
$219.06M
Revenue Growth
+7.52%
P/S Ratio
0.74
Revenue / Employee
$1,129,175
Employees
194
Market Cap
161.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 236.20M | 76.02M | 47.46% |
| Dec 31, 2024 | 160.18M | -34.44M | -17.70% |
| Dec 31, 2023 | 194.62M | -97.86M | -33.46% |
| Dec 31, 2022 | 292.48M | 80.83M | 38.19% |
| Dec 31, 2021 | 211.65M | -82.99M | -28.17% |
| Dec 31, 2020 | 294.64M | -40.36M | -12.05% |
| Dec 31, 2019 | 335.00M | 127.26M | 61.26% |
| Dec 31, 2018 | 207.74M | 26.52M | 14.63% |
| Dec 31, 2017 | 181.23M | 179.69M | 11,706.32% |
| Dec 31, 2016 | 1.54M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 457.45M |
| Organigram Global | 217.71M |
| Glass House Brands | 176.98M |
| Lifecore Biomedical | 129.46M |
| ADC Therapeutics | 79.58M |
| Journey Medical | 68.18M |
| SIGA Technologies | 53.66M |
| BGM Group | 47.90M |
AKBA News
- 16 days ago - Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum - GlobeNewsWire
- 17 days ago - Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026 - GlobeNewsWire
- 21 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Scynexis appoints Burke to Board of Directors - TheFly
- 5 weeks ago - Akebia doses first patient in ebribafusp trial - TheFly
- 5 weeks ago - Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases - GlobeNewsWire
- 6 weeks ago - Akebia initiated with a Buy at WestPark Capital - TheFly
- 7 weeks ago - Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - GlobeNewsWire